Patent EA-004295-B1 (EA)
Title: Method for treatment of streptococcus pneumoniae infections
Inventor: PARR THOMAS REEVES
IPC: A61P11/02
Filed: 2000-04-19
Abstract: 1. A method of treatment for long-term prevention of S. pneumoniae in susceptible individuals comprising administering to a susceptible individual an at least monthly effective dose of N<DISACC>-(4-(4-chlorophenyl) benzyl) A82846B or teicoplanin, or pharmaceutically acceptable salts, hydrates or solvates thereof, or mixtures thereof. 2. The method of Claim 1 wherein said monthly dose is >= 0.5 mg/kg body weight. 3. The method of Claim 1 wherein said monthly dose is from 0.5 mg/kg to 10 mg/kg body weight. 4. The method of Claim 1 wherein said monthly dose is from 0.5 mg/kg to 5 mg/kg body weight. 5. The method of Claim 1 wherein said monthly dose is from 0.5 mg/kg to 3 mg/kg body weight. 6. The method of Claim 1 wherein said monthly dose is from 0.5 mg/kg to 2.5 mg/kg body weight. 7. The method of Claim 1 wherein said monthly dose is administered orally. 8. The method of Claim 1 wherein said monthly dose is administered parenterally. 9.The use of N<DISACC>-(4-(4-chlorophenyl) benzyl) A82846B or teicoplanin, or pharmaceutically acceptable salts, hydrates or solvates thereof, or mixtures thereof, in the manufacture of a medicament useful for long-term prevention of S. pneumoniae in susceptible individuals. 10. The use as claimed in Claim 9, wherein the medicament is adapted for the periodic administration of an effective dose of N<DISACC>-(4-(4-chlorophenyl) benzyl) A82846B or teicoplanin, or pharmaceutically acceptable salts, hydrates or solvates thereof, or mixtures thereof, wherein the time interval between successive administrations is at least one month. 11. The use as claimed in any one of claims 9 or 10, wherein the medicament is adapted for the administration of N<DISACC>-(4-(4-chlorophenyl) benzyl) A82846B or teicoplanin, or pharmaceutically acceptable salts, hydrates or solvates thereof, or mixtures thereof in a dosage of greater than or equal to 0.5 mg/kg body weight. 12. The use as claimed in any one of claims 9 or 10, wherein the medicament is adapted for the administration of N<DISACC>-(4-(4-chlorophenyl) benzyl) A82846B or teicoplanin, or pharmaceutically acceptable salts, hydrates or solvates thereof, or mixtures thereof in a dosage from 0.5 mg/kg to 10 mg/kg body weight. 13. The use as claimed in any one of claims 9 or 10, wherein the medicament is adapted for the administration of N<DISACC>-(4-(4-chlorophenyl) benzyl) A82846B or teicoplanin, or pharmaceutically acceptable salts, hydrates or solvates thereof, or mixtures thereof in a dosage from 0.5 mg/kg to 5 mg/kg body weight. 14. The use as claimed in any one of claims 9 or 10, wherein the medicament is adapted for the administration of N<DISACC>- 4-(4-chlorophenyl) benzyl) A82846B or teicoplanin, or pharmaceutically acceptable salts, hydrates or solvates thereof, or mixtures thereof in a dosage from 0.5 mg/kg to 3 mg/kg body weight. 15. The use as claimed in any one of claims 9 or 10, wherein the medicament is adapted for the administration of N<DISACC>-(4-(4-chlorophenyl) benzyl) A82846B or teicoplanin, or pharmaceutically acceptable salts, hydrates or solvates thereof, or mixtures thereof in a dosage from 0.5 mg/kg to 2.5 mg/kg body weight.